News for Skye Bioscience, Inc. (SKYE)

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.17% to 40,592.77 while the ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up...

Skye Bioscience, under the ticker SKYE, has unveiled promising preclinical results for its innovative CB1 antibody, nimacimab. In a study examining diet-induced

Skye Bioscience (SKYE), a clinical-stage biopharmaceutical company, will attend the Piper Sandler Spring Biopharma Symposium. The event will be held on

**media[594185]**

Operator: Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today.

Skye Bioscience, Inc. (NASDAQ:SKYE) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ETCompany ParticipantsBernie Hertel - Head of Investor...

Enrollment completed in Phase 2a CBeyondâ„¢ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Ph

**media[572469]**

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. ( SKYE) (”œSkye”), a clinical-stage biotechnology company focused on unlocking new ther

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. ( SKYE) (”œSkye”), a clinical-stage biopharmaceutical company focused on unlocking new t

**media[548310]**

**media[531562]**

Expected Phase 2 obesity data in Q2 2025 and Q4 2025 will shape clinical potential and development path of distinctive CB1 inhibitor SAN DIEGO, Jan. 13, 2025

Despite risks related to early-stage IP and low trading volume, SKYE's promising IP and near-term catalysts justify a speculative

Skye Bioscience chief development officer sells shares worth $97,721

Skye Bioscience CFO Kaitlyn Arsenault sells $216,652 in stock

**media[468993]**

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. ( SKYE) (”œSkye”), a clinical-stage biopharmaceutical company focused on unlocking new t